Last update: Nov. 24, 2016
Minimal risk for breastfeeding and infant.
Proteolytic and lipolytic enzyme which is derived from mammalian pancreas that has protease, lipase and amylase activity. Indicated for treatment of cystic fibrosis and chronic pancreatitis.
At latest update no published data on excretion into breast milk was found.
Its high molecular weight and poor intestinal absorption make it highly unlikely a significant passage to the milk.
A low oral bioavailability hinders the passage into infant plasma from ingested milk.
It is a medication used in children and young infants.
We do not have alternatives for パンクレリパーゼ since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM